Medizinische Universität Graz - Research portal
Wenzl Heimo |
** = Publications listed in SCI/SSCI/Pubmed
2025
Full paper/article (Journal)
** Blesl, A; Binder, L; Halwachs, B; Baumann-Durchschein, F; Fürst, S; Constantini-Kump, P; Wenzl, H; Gorkiewicz, G; Högenauer, C
The Fecal Microbiome of IBD Patients Is Less Divertible by Bowel Preparation Compared to Healthy Controls: Results From a Prospective Study.
Inflamm Bowel Dis. 2025;
Doi: 10.1093/ibd/izaf053
Web of Science
PubMed
FullText
FullText_MUG
2023
Full paper/article (Journal)
** Blesl, A; Borenich, A; Gröchenig, HP; Novacek, G; Primas, C; Reinisch, W; Kutschera, M; Illiasch, C; Hennlich, B; Steiner, P; Koch, R; Tillinger, W; Haas, T; Reicht, G; Mayer, A; Ludwiczek, O; Miehsler, W; Steidl, K; Binder, L; Baumann-Durchschein, F; Fürst, S; Reider, S; Watschinger, C; Wenzl, H; Moschen, A; Berghold, A; Högenauer, C, , Austrian, IBD, Study, Group, (ATISG)
Factors Associated with Response to Systemic Corticosteroids in Active Ulcerative Colitis: Results from a Prospective, Multicenter Trial.
J Clin Med. 2023; 12(14):
Doi: 10.3390/jcm12144853
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Case Report
** Fabian, E; Roskaric, T; Pfeifer, J; Wenzl, H; Hammer, HF; Lackner, C; Rosanelli, G; Krejs, GJ
Clinical-Pathological Conference Series from the Medical University of Graz : Case No 166: An 82-year-old woman with voluminous diarrhea and weight loss.
Wien Klin Wochenschr. 2023; 135(15-16):429-435
Doi: 10.1007/s00508-022-02112-0
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2022
Full paper/article (Journal)
** Blesl, A; Petritsch, W; Binder, L; Fürst, S; Wenzl, H; Baumann-Durchschein, F; Kump, P; Högenauer, C
Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
Scand J Gastroenterol. 2022; 57(11):1327-1330
Doi: 10.1080/00365521.2022.2088248
Web of Science
PubMed
FullText
FullText_MUG
2021
Full paper/article (Journal)
** Blesl, A; Binder, L; Högenauer, C; Wenzl, H; Borenich, A; Pregartner, G; Berghold, A; Mestel, S; Kump, P; Baumann-Durchschein, F; Petritsch, W
Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.
Aliment Pharmacol Ther. 2021; 54(5):667-677
Doi: 10.1111/apt.16478
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Comment
** Blesl, A; Högenauer, C; Borenich, A; Berghold, A; Wenzl, H; Petritsch, W
Editorial: does anti-TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply.
Aliment Pharmacol Ther. 2021; 54(5):720-721
Doi: 10.1111/apt.16535
Web of Science
PubMed
FullText
FullText_MUG